Ventilator-associated pneumonia in long-term ventilator-assisted individuals

Spinal Cord. 2010 Dec;48(12):876-80. doi: 10.1038/sc.2010.43. Epub 2010 Apr 20.

Abstract

Background: Information on the characteristics of pneumonia in long-term ventilator-assisted individuals is scarce. We evaluate the incidence, risk factors and outcome of ventilator-associated pneumonia (VAP) in a large series of chronically ventilated patients.

Methods: All patients assisted in a chronic ventilator-dependent unit were prospectively followed up for the development of VAP. Patients with a new and persistent lung infiltrate and a purulent tracheal aspirate were suspected to have VAP. Pneumonia was considered microbiologically confirmed in the presence of (1) a positive blood culture and/or (2) ≥10⁵ CFU ml⁻¹ in quantitative bacterial culture of tracheal aspirates or ≥10³ CFU ml⁻¹ in quantitative mini-bronchoalveolar lavage cultures.

Results: In total, 100 consecutive long-term ventilated individuals with spinal cord injury (mean age 49 years) were prospectively followed up. The length of mechanical ventilation before admission in the unit was 54±37 days, and the follow-up after admission was 119±127 days. There were 32 episodes of VAP in 27 patients (1.74 episodes per 1000 days of mechanical ventilation). By logistic regression analysis, hypoalbuminaemia (P=0.03), administration of antacids (P=0.002) and length of mechanical ventilation (P=0.05) were independent risk factors for VAP. The most frequently isolated organisms were Pseudomonas aeruginosa (62%), methicillin-resistant Staphylococcus aureus (25%) and Acinetobacter baumannii (15%); 9 (28%) episodes were polymicrobial. Antimicrobial treatment, including monotherapy in 66%, was successful in most patients. Only three patients (11%) died in relation to VAP.

Conclusions: Patients on long-term ventilation are at significant risk for the development of VAP, but the mortality is low.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Female
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Pneumonia, Ventilator-Associated / drug therapy
  • Pneumonia, Ventilator-Associated / epidemiology*
  • Pneumonia, Ventilator-Associated / microbiology*
  • Risk Factors
  • Spinal Cord Injuries / complications
  • Spinal Cord Injuries / physiopathology

Substances

  • Anti-Bacterial Agents